Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
| ▸ | F11 | P03951 | 2/20 | 0.42 |
| ▸ | SPR | P35270 | 2/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.39 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.39 |
| ▸ | CCKBR | P32239 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
| ▸ | USP5 | P45974 | 1/20 | 0.37 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17134873 | 0.94 | CA12 (0.40) | CA12CA1CA2CA7CA9 | |
| SCHEMBL17134971 | 0.85 | SCD (0.36) | ALDH1A1MGLL | |
| SCHEMBL17134826 | 0.81 | VNN1 (0.43) | — | |
| SCHEMBL17134602 | 0.80 | IDO1 (0.46) | CA12CA1CA2CA7CA9 | |
| SCHEMBL17135011 | 0.80 | SPR (0.46) | CA12CA1CA2CA7CA9 | |
| SCHEMBL17134703 | 0.79 | SCD5 (0.39) | CA12CA1CA2CA7CA9 | |
| SCHEMBL17292884 | 0.78 | DRD4 (0.44) | CA12CA1CA2CA7CA9 | |
| SCHEMBL17134702 | 0.78 | KMT2A (0.47) | CA12CA1CA2CA7CA9 | |
| SCHEMBL17135064 | 0.77 | CCR1 (0.46) | CA12CA1CA2CA7CA9 | |
| SCHEMBL17134918 | 0.77 | P2RX7 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2927214-B1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | KYOWA HAKKO KIRIN CO LTD (JP) | 2018-03-21 | — | — | EP | disclosed |
| US-9701689-B2 | Substituted pyridines and pyridazines as CCR10 receptor inhibitors | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2017-07-11 | — | — | US | disclosed |
| US-20150299214-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2015-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299214-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | ARG1, H1-0, TYR | CA12 1854/4885CA1 2565/4885CA2 1307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.